Cuproptosis In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications. [1]
Cuproptosis is a recently identified form of regulated cell death driven by copper-dependent proteotoxic stress. Discovered in 2022, this copper-induced cell death mechanism has emerged as a potentially important pathway in neurodegenerative diseases, where copper dyshomeostasis is frequently observed. [2]
Unlike apoptosis (which is caspase-dependent) or ferroptosis (which is iron-dependent), cuproptosis is characterized by direct copper binding to lipoylated TCA cycle proteins, leading to proteotoxic stress and cell death. This mechanism may contribute to the neuronal loss observed in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [3]
| Protein | Role in Cuproptosis |
|---|---|
| DLAT | Dihydrolipoamide S-acetyltransferase, primary copper target |
| DLST | Dihydrolipoamide S-succinyltransferase, TCA cycle enzyme |
| PDH Complex | Pyruvate dehydrogenase, lipoylated protein target |
| CTR1 (SLC31A1) | High-affinity copper transporter |
| ATP7A/ATP7B | Copper-transporting ATPases |
| MT3 | Metallothionein-3, copper buffering |
| CCS | Copper chaperone for SOD1 |
| ATOX1 | Antioxidant protein 1, copper chaperone |
The brain maintains strict copper homeostasis through:
Alzheimer's Disease:
Parkinson's Disease:
Amyotrophic Lateral Sclerosis (ALS):
Copper chelators represent the primary therapeutic approach for modulating cuproptosis:
| Agent | Mechanism | Clinical Status | Reference |
|---|---|---|---|
| Trientine | Selective copper chelation | Approved for Wilson's disease | [4] |
| Tetrathiomolybdate (TTM) | Copper-binding protein induction | Investigational | [5] |
| Penicillamine | Copper chelation + excretion | Approved (Wilson disease) | [6] |
| EDTA | Non-specific metal chelation | Limited CNS penetration | [7] |
| Baicalein | Natural copper chelator | Preclinical | [8] |
Beyond direct chelation, modulating copper transport proteins offers therapeutic potential:
CTR1 (SLC31A1) Modulation
ATP7A/ATP7B Enhancement
Metallothionein Modulation
CuATSM (Copper(II)-diacetyl-bis(N4-methylthiosemicarbazone)):
| Dimension | Score (1-10) | Rationale |
|---|---|---|
| Mechanistic Clarity | 8 | Well-defined copper-DLAT interaction pathway |
| Genetic Evidence | 7 | ATP7A/ATP7B mutations; SLC31A1 variants in PD |
| Biomarker Availability | 5 | Serum copper; limited CNS-specific markers |
| Therapeutic Targetability | 7 | Multiple druggable nodes (chelators, transporters) |
| Clinical Trial Readiness | 6 | Existing chelators can be repurposed |
| Safety Window | 5 | Copper homeostasis is delicate; narrow therapeutic window |
| Disease Relevance | 8 | Strong evidence across AD, PD, ALS |
| Combination Potential | 7 | Works with antioxidants, anti-aggregates |
| Biomarker Accessibility | 4 | Brain imaging challenging; peripheral markers incomplete |
| Regulatory Pathway | 6 | Repurposing existing chelators possible |
| TOTAL | 63/100 |
Interpretation: Moderate-to-high priority target. The mechanistic basis is solid, but delivery to the CNS and safety monitoring remain challenges. Best suited for combination therapy approaches.
| Risk | Mitigation |
|---|---|
| CNS penetration failure | Focus on TTM, intranasal delivery |
| Safety concerns | Start low-dose, careful monitoring |
| Patient heterogeneity | Biomarker-based stratification |
| Competition | Establish IP on novel combinations |
Tsvetkov et al. Copper induces cell death via targeting lipoylated TCA cycle proteins (2022). 2022. ↩︎
Wang et al. Copper Metabolism in Neurodegenerative Diseases (2022). 2022. ↩︎
Kaler et al. ATP7A and ATP7B in Neurodegeneration (2021). 2021. ↩︎